21/04/2017 12:30:00

Repligen to Report First Quarter 2017 Financial Results

Related content
17 Jan - 
Report: Developing Opportunities within Repligen, Avid ..
29 Dec - 
Repligen To Present at 36th Annual J.P. Morgan Healthca..
09 Nov - 
Repligen Reports Third Quarter 2017 Financial Results

WALTHAM, Mass., April 21, 2017 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report first quarter of 2017 financial results on Thursday, May 4, 2017. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the reporting periods ended March 31, 2017. 

The conference call will be accessible by dialing toll-free (844) 835-7432 for domestic callers and (404) 537-3372 for international callers. Dial-in participants must provide the passcode 11424546. In addition, a webcast will be accessible via the Investor Relations section of the Company's website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Replay listeners must provide the passcode 11424546. 

About Repligen Corporation

Repligen Corporation (NASDAQ:RGEN) is a bioprocessing company focused on the development, manufacture and commercialization of highly innovative products used to improve the interconnected phases of the biological drug manufacturing process. Our portfolio includes protein products (Protein A affinity ligands, cell culture growth factors), chromatography products (OPUS® pre-packed columns, chromatography resins, ELISA kits) and filtration products (XCell™ ATF Systems, TangenX™ Sius™ TFF cassettes). Our bioprocessing products are sold to major life sciences companies, biopharmaceutical development companies and contract manufacturing organizations worldwide. The Protein A ligands and growth factor products that we manufacture are components of chromatography resins and cell culture media, respectively. We are the leading manufacturer of Protein A ligands, a critical component of Protein A resins that are the industry standard for downstream separation and purification of monoclonal antibody-based therapeutics. Our growth factors are used in upstream processes to accelerate cell growth and productivity. Our innovative line of OPUS® chromatography columns, used in downstream processes for bench-scale through clinical-scale purification needs, are delivered pre-packed with our customers' choice of resin and bed height. Our XCell™ ATF Systems, available in stainless steel and single-use configurations, continuously eliminate waste from a bioreactor to concentrate cells and increase productivity in upstream processes. Single-use Sius™ TFF cassettes and hardware are used for biologic drug concentration in downstream processes. Repligen's corporate headquarters are in Waltham, MA (USA) and our manufacturing facilities are located in Waltham, MA, Shrewsbury, MA, Lund, Sweden and Weingarten, Germany. 

This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like "believe," "expect," "may," "will," "should," "seek," or "could" and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.

Contact:

Sondra Newman

Senior Director Investor Relations

(781) 419-1881

snewman@repligen.com

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Man Group PLC : Form 8.3 - [UBM plc] - Amendment

22/01/2018 14:52:32
Amendment to cash-settled derivatives positions and transactions, sections 2(a) and 3(b). FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: ..

Boussard & Gavaudan Investment Management LLP : Form 8.3 - UBM Plc

22/01/2018 13:22:35
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a)  Identity of the person whose positions/dealings are being disclosed: Boussard & Gavaudan Investment Manage..

Dimensional Fund Advisors Ltd. : Form 8.3 - Tesco Plc - Ordinary shares

22/01/2018 10:54:08
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser:   Dimensional Fund Advisors Ltd. ("Dimensional"), in its capacity ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
PacketFabric Announces Scalable Connectivity to Multiple Cloud Service Providers
2
Pulse Larsen Antennas will showcase its RAZORBACK, ARMADILLO, FIN, PANTHER, JAGUAR, DISC antenna series. Available in black and white, with three mounting types (direct, adhesive and magnet).
3
Genmab Announces Novartis’ Intention to Transition Arzerra® (ofatumumab) from Commercial Availability to Limited Availability via Compassionate Use Programs for the Treatment of CLL in Non-US Markets
4
West’s Unified Communications Services Attains Cisco Powered Cisco Spark Service Provider Designation
5
Canadian Nanosatellite Launch from China Heralds New Era of Satellite Services

Related stock quotes

Repligen Corporation 35.89 0.0% Stock price unchanged

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
23 January 2018 00:19:51
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180122.2 - EUROWEB5 - 2018-01-23 01:19:51 - 2018-01-23 00:19:51 - 1000 - Website: OKAY